Table 1.
Molecules | Mechanism | Induction of pancreatic lineage markers | Reference | Humans | Rodents | ||
---|---|---|---|---|---|---|---|
TGF-β inhibition | SB431542 | Inhibits ALK 4/5/7 | Upregulates INS gene expression and C-peptide+ cells | Nostro et al. (15) | √ | ||
SB431542 + RA | Upregulates PDX1 gene expression | Cho et al. (16) | √ | ||||
TGF-βRI kinase inhibitor IV | Induces pancreatic progenitors from hPSCs | Schultz et al. (17) | √ | ||||
1 μM ALK5iII | Inhibits ALK5 | Downregulates NGN3. Upregulates NEUROD, INS, GCG, and SST transcripts Induces Mafa transcript expression in diabetic rodents |
Rezania et al. (4, 6, 18) | √ | √ | ||
10 μM ALK5iII | Pagliuca et al. (7) | √ | |||||
Protein kinase C signaling | 300 nM ILV | Activates PKC Synergizes with FGF10 signaling |
Upregulates gene expression of pancreatic progenitor markers SOX9, PDX1, PTF1A, HNF6, PROX1 Upregulates gene expression of endocrine progenitor markers including NGN3, NKX2.2, and NKX6.1 |
Chen et al. (26) | √ | √ | |
500 nM TPB | Upregulates protein expression of FOXA2, PTF1A, HNF6, and NKX6.1 | √ | |||||
14 nM PMA | Downregulates protein expression of endoderm markers CDX2 and AFP | √ | |||||
50 nM TPB | Activates PKC | Upregulates gene expression of pancreatic lineage markers NGN3, NEUROD1, PTF1A, and NKX6.1 Downregulates gene expression of intestinal marker CDX2 and liver marker ALB |
Rezania et al. (4) | √ | |||
500 nM PDBu | Pagliuca et al. (7) | √ | |||||
Low retinoic acid (RA) signaling | 1–3 μM RA | Activates RA receptors | Various | √ | |||
3 nM TTNPB | Schulz et al. (17) | √ | |||||
1 μM → 100 nM → 50 nM RA | Rezania et al. (7) | √ | |||||
2 μM → 100 nM → 25 nM RA | Pagliuca et al. (7) | √ | |||||
γ-secretase/Notch inhibitor | DAPT | Inhibits Notch signaling | Upregulates NGN3 mRNA and protein expression in adult islets | Dror et al. (36) | √ | √ | |
Upregulates NGN3 and NEUROD1 gene expression | Rezania et al. (18) | √ | |||||
GSiXX | Upregulates expression of β cell maturation genes Downregulates expression of pancreatic exocrine marker PTF1A |
Rezania et al. (6) | √ | ||||
GSiXX + T3 | Upregulates NKX6.1+insulin+GCG- β-like cells | Rezania et al. (6) | √ | ||||
1 μM XXI | Upregulates β cell gene expression | Pagliuca et al. (7) | √ | ||||
T3 | 0.1 μM T3 | Activates MAPK/ERK signaling pathway | Induces rodent pancreatic β cell proliferation | Kim et al. (42) | √ | ||
1 μM T3 | Upregulates expression of INS and mature β cell markers | Rezania et al. (6) | √ | ||||
Enhances co-expression of NKX6.1 and INS protein | Pagliuca et al. (7) | ||||||
AXL | 2 μM BGB324 (R428) | Inhibits AXL | Upregulates MAFA protein expression | Rezania et al. (6) | √ | ||
GAS6 | Activates AXL | Downregulates Mafa gene expression | Haase et al. (48) | √ | |||
Antioxidants | GPx-1 | Antioxidants | Maintains protein expression of nuclear MAFA in diabetic rodents | Harmon et al. (22) | √ | ||
NAC | Harmon et al. (21) | √ | |||||
Ebselen | Mahadevan et al. (20) | √ | |||||
1–2 mM NAC | Upregulates nuclear MAFA protein expression | Rezania et al. (6) | √ | ||||
0.25 mM vitamin C | Generates mature and functional human pancreatic β cells | Pagliuca et al. (7) | √ | ||||
Betacellulin | BTC | Binds to ErbB-1 and ErbB-4 receptors to initiate PI3K/Akt, MAPK, STAT, and mTOR signaling pathways | Upregulates insulin secretion | Dahlhoff et al. (65) | √ | ||
Upregulates mRNA and protein expression of IRS-2 | Oh et al. (68) | √ | |||||
Induces Pax4 gene expression in rat islets | Brun et al. (70) | √ | |||||
Sustains PDX1 expression and induces β cell differentiation from hESCs | Cho et al. (71) | √ | |||||
10 ng/ml BTC | Upregulates Pdx1 gene expression and insulin production Downregulates amylase and glucagon production in mouse embryonic pancreas explants |
Thowfeequ et al. (72) | √ | ||||
20 ng/ml BTC | Induces pancreatic differentiation | Pagliuca et al. (7) | √ | ||||
50 ng/ml EGF | Preserves cell mass | Schulz et al. (17) | √ |
BTC, Betacellulin; DAPT, N-[N-(3,5-difluorophenacetyl-l-alanyl)]-S-phenylglycine t-butyl ester; GPx-1, glutathione peroxidase-1; GSiXX, γ secretase inhibitor XX; ILV, (−)-indolactam V; NAC, N-acetylcysteine; PDBu, phorbol 12,13-dibutyrate; PMA, phorbol-12-myristate-13-acetate; T3, l-3,3′,5-Triiodothyronine; TPB, [(2S,5S)-(E,E)-8-(5-(4-(trifluoromethyl)phenyl)-2,4-pentadienoylamino) benzolactam].